An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and thymosin beta-4. The panel rejected emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem's stock remained stable after the vote. A recent study indicated peptides may assist with combating antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for expanded access to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how regulators view compounded peptide therapies, which have drawn growing interest from consumers seeking alternatives to conventional drugs. Investigators say peptide treatments could reshape approaches to difficult infections, though concerns about safety persist. The committee's endorsement of four peptides opens the door for more broad prescribing, even as critics warn of short-term evidence. Sector observers note that peptide-focused companies may see heightened investor attention following the panel's decision. The rejection of emideltide, meanwhile, underscores the FDA's cautious stance on particular peptide candidates.